Why this index exists
Bringing a laboratory-based IVD test to European outpatient markets can mean navigating different reimbursement lists, payment mechanisms, payer decisions and health technology assessment (HTA) processes. Even when two countries offer similar testing opportunities, the formal route to payment can differ substantially in complexity, evidence burden and predictability.
The Index helps you answer:
Where can we get to first meaningful revenue fastest?
Which countries have clear, repeatable market access pathways and which are “case-by-case”?
2027 IVD EU Market Access Attractiveness Index
| Country | MAAI |
|---|---|
Denmark
|
75
|
Norway
|
68
|
Netherlands
|
63
|
France
|
60
|
Switzerland
|
60
|
Belgium
|
53
|
Germany
|
53
|
Sweden
|
53
|
Spain
|
50
|
England
|
40
|
Austria
|
30
|
Italy
|
20
|
The 2027 MAAI ranking highlights significant differences across Europe in the attractiveness of market access conditions for outpatient IVD tests.
Denmark leads the ranking, followed by Norway and the Netherlands, driven primarily by limited formal access barriers, manageable evidence requirements, and predictable processes. France stands out for its highly active innovative payment schemes, while Switzerland benefits from a fast and predictable national reimbursement pathway, despite formal access requirements.
A clear middle tier (Belgium, Germany, Sweden, Spain) reflects relatively structured but constrained systems, where moderate predictability, evidence requirements, or regional complexity limit overall attractiveness. Sweden and Spain particularly illustrate how fragmented regional decision-making can offset otherwise favorable conditions.
At the lower end, England, Austria, and Italy face different challenges, including demanding evidence requirements and multiple access barriers (England), unpredictable timelines and decentralized decisions (Austria), and extensive national and regional barriers combined with low predictability (Italy).
Overall, the index shows that structural access barriers and evidence requirements, rather than speed alone, are the strongest drivers of market access attractiveness, with less restrictive and more predictable pathways consistently outperforming fragmented and demanding systems.
Explore the full report
Request the full 2027 report to examine the methodology, pillar scores and country-specific considerations behind the ranking. Report is only available to representatives of IVD and medical technology companies.
What MAAI measures (6 pillars)
MAAI converts six core market access realities into a single 0–100 score (higher = more attractive).
Counts the number of material market access barriers (“gates”) that must be overcome to obtain market access for in-scope IVD tests.
How reliably the system behaves: pathway clarity, transparency of criteria, stability of outcomes, and consistency of timelines.
The time from application to removal of the formal barriers relevant to routine payment and use.
The typical clinical and health economic evidence expectations.
Does the country offer innovative payment schemes to support early access for medical devices?
Does this country require laborious regional market access activities in comparison with the national approach?
The 2027 Index covers standard laboratory-based outpatient IVD tests. It excludes companion diagnostics, mass screening tests and point-of-care tests. The Index assesses formal access conditions, not market size, reimbursement tariff adequacy, procurement, clinical adoption or commercial success.
Each country receives a score for the six pillars. The overall index is a weighted combination:
Weights are published in the methodology and available on demand to representatives of the IVD and medical device industry.